# Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)

Source: https://onco.cc/trials/nct01906385/  
OnCo record `nct01906385` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Rhenium Liposome Treatment in glioma & glioblastoma, run by Cerenome, now recruiting.

## Summary

Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) is a phase 1/2 interventional study registered as NCT01906385 by Cerenome, with 55 participants planned, started 2015-06-03 and due to reach its primary completion in 2025-12. Interventions recorded: Rhenium Liposome Treatment.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01906385
- Phase: 1/2
- Setting: A Dual Phase 1/2, Investigator Initiated Study to Determine the Maximum Tolerated Dose, Safety, and Efficacy of 186Rhenium Nanoliposomes (186RNL) in Recurrent Glioma (CTRC# 12-02)
- Sponsor: Cerenome
- Enrolled: 55

## Sources

- ClinicalTrials.gov NCT01906385: https://clinicaltrials.gov/study/NCT01906385

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)

---
JSON: https://onco.cc/api/v1/entities/nct01906385.json